文献速递瓣膜病与结构性心脏病

脑栓塞保护对TAVI术后认知功能的影响:BHF PROTECT-TAVI随机试验数据

Impact of Cerebral Embolic Protection on Cognitive Function After Transcatheter Aortic Valve Implantation: Data From the BHF PROTECT-TAVI Randomized Trial.
PubMed 文献 · Circulation · 2025-08-30

该研究为BHF PROTECT-TAVI试验的二次分析,纳入英国33个中心3535例接受TAVI的主动脉瓣狭窄患者,随机分至SENTINEL脑栓塞保护(CEP)组或对照组。主要终点为基线至术后6-8周的电话版蒙特利尔认知评估(t-MoCA)均数变化,结果显示两组间无差异(-0.07,95%CI -0.22至0.09,P=0.42),CEP未影响TAVI术后认知功能。

要点

  • CEP组与对照组t-MoCA均数变化无差异(-0.07,95%CI -0.22至0.09,P=0.42)。
  • t-MoCA下降≥3分的发生率两组分别为8.7%与8.0%,风险差0.72%(95%CI -1.10至2.55,P=0.44)。
  • 亚组分析未发现治疗分配与任何亚组间的交互作用证据。

核心结论

  • 在BHF PROTECT-TAVI试验中,使用脑栓塞保护装置未影响TAVI术后的认知功能。

研究设计与样本

  • BHF PROTECT-TAVI试验的二次分析,纳入英国33个中心因主动脉瓣狭窄接受TAVI的患者,按1:1随机分至SENTINEL CEP组或对照组。
  • 本分析仅限完成认知评估者,改良意向治疗人群共3535例,SENTINEL CEP组1763例,对照组1772例,平均年龄81.0岁,女性37.7%。

主要发现

  • 基线t-MoCA中位数18(四分位距16-20),6-8周时中位数20(四分位距17-21)。
  • 调整基线评分后,基线至6-8周t-MoCA总分的均数变化在SENTINEL CEP组为0.83(95%CI 0.70-0.96),对照组为0.91(95%CI 0.79-1.04),组间均数差为-0.07(95%CI -0.22至0.09,P=0.42)。
  • t-MoCA总分下降≥3分的发生率在SENTINEL CEP组为154/1763(8.7%),对照组为142/1772(8.0%),风险差0.72%(95%CI -1.10至2.55,P=0.44)。
  • 上述结果在敏感性分析中稳健,且未发现治疗分配与所评估的任何亚组之间存在交互作用的证据。

临床怎么用

  • 对于接受TAVI的主动脉瓣狭窄患者,不应期望通过常规使用CEP装置来改善术后短期认知功能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In addition to the risk of stroke, patients undergoing transcatheter aortic valve implantation (TAVI) are susceptible to a decline of neurocognitive function. This may occur because of embolization of material (eg, valve or calcium) to the brain. Cerebral embolic protection (CEP) devices are engineered to capture this debris, potentially mitigating its incidence. METHODS: This is a secondary analysis of the BHF PROTECT-TAVI trial (British Heart Foundation Randomized Trial of Routine Cerebral Embolic Protection in Transcatheter Aortic Valve Implantation), in which participants with aortic stenosis from across 33 centers in the United Kingdom were randomly assigned at a 1:1 ratio to undergo TAVI with a CEP device (SENTINEL, Boston Scientific; SENTINEL CEP group) or TAVI without a CEP device (control group). This analysis is restricted to those who underwent cognitive assessment. The primary outcome was the mean change in the telephone version of the Montreal Cognitive Assessment (t-MoCA) between baseline and 6 to 8 weeks after TAVI. The secondary outcome was a ≥3-point drop in total t-MoCA score between baseline and 6 to 8 weeks after TAVI. RESULTS: A total of 3535 participants, 1763 in the SENTINEL CEP group and 1772 in the control group (mean age 81.0 years, 37.7% women) randomized in BHF PROTECT-TAVI were included in the modified intention-to-treat population for this analysis. The median t-MoCA at presentation was 18 (interquartile range, 16-20). The median t-MoCA at 6 to 8 weeks was 20 (interquartile range, 17-21). The mean change in total t-MoCA score between baseline and 6 to 8 weeks adjusted for the baseline score was 0.83 (95% CI, 0.70-0.96) in the SENTINEL CEP group and 0.91 (95% CI, 0.79-1.04) in the control group. There was no difference in means between the treatment groups (-0.07 [95% CI, -0.22 to 0.09], P=0.42). The incidence of a ≥3-point drop in the total t-MoCA score was 154 of 1763 (8.7%) in the SENTINEL CEP group and 142 of 1772 (8.0%) in the control group. The corresponding risk difference was 0.72% (95% CI, -1.10 to 2.55; P=0.44). These findings were robust to sensitivity analyses. There was no evidence of an interaction between treatment assignment and any of the subgroups assessed. CONCLUSIONS: In the BHF PROTECT-TAVI trial, the use of CEP did not impact cognition after TAVI. REGISTRATION: URL: https://www.isrctn.com; Unique identifier: ISRCTN16665769.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Kennedy J, Blackman DJ, Dodd M, et al. Impact of Cerebral Embolic Protection on Cognitive Function After Transcatheter Aortic Valve Implantation: Data From the BHF PROTECT-TAVI Randomized Trial. Circulation. 2025. PMID: 40884786. doi:10.1161/CIRCULATIONAHA.125.076761

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。